Background-One sixth of US dialysis patients 65 years of age have been diagnosed with atrial fibrillation/flutter (AF).
to indicate ESRD status of each patient, and the ESRD Death Notification Form (CMS-2746).
We identified all patients initiating chronic dialysis between January 1, 1995 and December 31, 2007, who were aged Ն67 years when starting dialysis. Using the USRDS payor history file, we retained only those patients who had at least 2 years of uninterrupted fee-for-service Medicare coverage before their reported first dialysis (first service date). For these individuals, we can reliably capture 2 years of their Medicare-reimbursed healthcare claims and associated diagnoses and procedures before ESRD. We then removed all individuals with any recorded diagnosis of atrial fibrillation or atrial flutter in the 2 years preceding first dialysis, as indicated by presence of any ICD-9 codes of 427.3, 427.31, or 427.32 in any Part A or B claims.
Definition of Atrial Fibrillation and Other Outcomes
Selected individuals were followed for 1 of 3 potential events: incident AF (atrial fibrillation or flutter), death, or kidney transplantation. Incident AF was determined by the presence of 1 inpatient or 2 outpatient diagnoses for AF. Such an approach has been used to identify Medicare patients for the National Registry of Atrial Fibrillation 11 and other claims-based research studies of AF. [12] [13] [14] [15] This approach has been shown to have a sensitivity of 94%, specificity of 99%, and positive predictive value (PPV) of 97%. 16 -19 As secondary end points, we examined trends in death and ischemic stroke after AF. Death and kidney transplantation were determined using USRDS standard analytic files. To define stroke, we identified inpatient claims for the presence of International Classification of Diseases, 9
th Revision (ICD-9) codes 433, 434, or 436 (any 4th or 5th digit). If none of the events occurred before December 31, 2008 , individuals were administratively censored based on the earlier of their last observed claim date or 12/31/08.
Other Variables of Interest
To describe trends in incident AF, the primary covariate of interest was year of initiation of dialysis. For analyses of trends in mortality after AF, we focused on year of incident AF. To allow for nonlinear time trends, year was treated as a categorical variable for both analyses. Secondary covariates of interest were sex, race (white, black, Asian, Native American, other), and ethnicity (Hispanic versus non-Hispanic) as reported on the Medical Evidence Report.
Additional Variables for Multivariable Adjustment
A large number of additional comorbidities and health-relevant characteristics were ascertained from the Medical Evidence Report. This information included the following: body mass index (coded as a 4-level categorical variable: underweight, Ͻ18.5 kg/m 2 ; normal weight, 18.5 to Ͻ25 kg/m 2 ; overweight, 25 to Ͻ30 kg/m 2 ; obese, Ն30 kg/m 2 ), receipt of an erythropoiesis-stimulating agent before onset of ESRD, presence (but not severity) of atherosclerotic heart disease, heart failure, peripheral vascular disease, cerebrovascular disease, hypertension, diabetes mellitus, malignant neoplasm/cancer, chronic obstructive pulmonary disease, immobility (inability to ambulate or transfer), current smoking, drug dependence, alcohol dependence, as well as the initial dialysis modality used (peritoneal or hemodialysis).
Statistical Analysis
All analyses were conducted in R version 2.14 (The R-Project for Statistical Computing, Vienna, Austria). We defined the incidence rate of AF by dividing the number of observed cases by the number of person-years at risk. Unadjusted time trends were first examined by analyzing the probability of an AF diagnosis within 1 year of ESRD diagnosis over time. These analyses were conducted in the full study population as well as in strata defined by sex, race, and ethnicity (Hispanic versus non-Hispanic).
Using date of ESRD as the index date, 3 survival models were fit to examine changes in risk of AF based on year of dialysis initiation. First, an unadjusted model only using year of incident ESRD was fit. A second model adjusted for the baseline demographics of age, sex, race, and ethnicity. A final fully adjusted model using comorbidities from the Medical Evidence Report as well as dialysis modality was fit.
In this analysis, both transplantation and death serve as competing risks for AF. We examined the association of year with incident AF using both a traditional (cause-specific hazard) 20 as well as a competing risk approach (subdistribution hazard). 21 Each has a slightly different interpretation, with the cause-specific hazard estimating the risk of AF in the absence of the competing events, and the subdistribution hazard the real-world risk of AF. All covariates were examined for violation of proportional hazards by analyzing Schoenfeld residuals.
To describe mortality after a new AF diagnosis, additional Cox models were fit. Date of AF was used as the index date, which was the date of the second AF claim if the first claim was an outpatient claim to avoid including immortal person time as a result from our algorithm to ascertain AF. To analyze time trends, year of AF diagnosis was the primary covariate of interest while adjusting for demographic factors. Comorbidities were not used for this analysis, and all analyses were adjusted for years since the first date of ESRD treatment. Although transplantation does serve as a competing risk, in this population transplantation is extremely rare (Ͻ1%) so the cause-specific hazard was estimated, which will be virtually identical to the subdistribution hazard.
Finally, to assess temporal trends in the incidence of ischemic stroke after a new diagnosis of AF, all individuals with a previously recorded stroke (either before ESRD or between ESRD and first AF date) were excluded. We then estimated both the cause-specific and the subdistribution hazard ratios, with death as the competing risk.
We presented hazard ratios accompanied by their 95% confidence intervals (CI). An internal review board at Stanford University School of Medicine approved this study.
Results

Study Cohort
The cohort selection is shown in Figure 1 . Among all older patients initiating dialysis between 1995 and 2007, 382 495 were identified as having had 2 years of previous uninterrupted fee-for-service Medicare coverage. Among these, 115 481 (30%) had 1 or more previous diagnosis claims for AF and were excluded from the analysis. The proportion of patients with AF diagnosed before initiation of dialysis increased from 24% in 1995 to 33% in 2007. In addition, 729 (0.3%) died on their first service date or were preemptively transplanted and 7680 (3%) were missing their Medical Evidence Report and also excluded. The remaining 258 605 were followed for the development of AF, death, or transplantation ( Figure I in the online-only Data Supplement). Of the full cohort, 29% developed AF before death or transplantation, whereas 55% died without developing AF. Few members of the cohort were transplanted (1.3%), whereas 14% were administratively censored.
The primary covariate of interest was incident year. Table  1 shows the characteristics of the study cohort, overall as well as broken down by year of incident ESRD (1995 ESRD ( -1999 2000 2004 . Although almost all characteristics differed significantly across years owing to the large sample size, some noticeable trends appear. The average age was older, more patients were male, and the racial breakdown included more whites and fewer blacks in more recent years. The prevalences of hypertension and diabetes mellitus have increased, as has the average body mass index. There has also been a steady increase in the reported use of erythropoiesisstimulating agents before initiation of dialysis.
Baseline characteristics were also explored based on observed outcome (Table I in the online-only Data Supplement). Those developing AF were more likely to be non-Hispanic and white. They were also less likely to have received predialysis erythropoietin and less likely to have had diabetes mellitus. As expected, patients receiving a kidney transplant were systematically younger and healthier.
Time Trends in Incident Atrial Fibrillation
Over 514 395 person-years of follow-up, 76 252 patients developed AF for a crude AF incidence rate of 148/1000 person-years. Of these patients with incident AF, 75.6% had a first AF diagnosis as inpatients. To explore the time trends in AF, the probabilities of developing AF within 1 year based on incident year were stratified on sex, race, and ethnicity (Hispanic versus Non-Hispanic; Figure 2 ). The probability of developing AF during the first year after initiation of dialysis has increased over time, from 11.3% in patients initiating dialysis in 1995 to 14.5% among those who did so in 2007. Although there was only a small difference by sex, whites (versus all other races) and non-Hispanics (versus Hispanics) appeared at increased risk. For the most part the excess incidences observed for whites and Non-Hispanics appeared to be proportional. A Kaplan-Meier plot ( Figure II in the online-only Data Supplement) also suggests an increasing risk of AF over time. Data are presented as percentage or mean (Ϯstandard deviation). ASHD indicates artherosclerotic heart disease; BMI, body mass index; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; and HD, hemodialysis.
Multivariable Associations With Incident Atrial Fibrillation
To more formally examine time trends in AF, a series of time-to-event models with AF as the outcome and incident year as the primary covariate of interest were fit to the data. Table 2 shows the results of the 3 models, and Figure 3 displays the changing relative hazard for each of the models over time. A likelihood ratio test for incident year was highly significant. The unadjusted model showed a steady increase in the risk of AF over time (P for trend Ͻ10 Ϫ8 ); however, much of the association was attenuated when adjusting for baseline covariates. There was an increase in AF incidence from 1995 to 2003, whereas the incidence remained relatively stable or declined slightly from then to 2007. These analyses estimated the cause-specific hazard, however analyses using a competing risk framework showed that trends in the subdistribution hazard were slightly more pronounced, but overall very similar (Table II in the online-only Data Supplement).
As already suggested by Figure 2 , Hispanic individuals had a substantially lower incidence of AF compared with nonHispanic patients (Ϫ29%). Compared with non-Hispanic whites, blacks (Ϫ30%), Asians (Ϫ29%), and Native Americans (Ϫ42%) were also at substantially lower risk of incident AF. We observed only minimal differences between males and females. Not surprisingly, many baseline factors were associated with an increased risk of AF (not shown). Although many of these covariates formally violated proportional hazards, examination of the residuals suggested that they would not impact the results. Sensitivity analyses were performed, treating these covariates as stratification variables, and the effect estimates on incident year were not noticeably impacted.
Death After Newly Diagnosed Atrial Fibrillation
The 76 252 people who developed AF were analyzed for their risk of death (Figure 1 ). Over 92 426 person-years of followup, 65 298 patients died, for a mortality rate of 706/1000 person-years, with 1-year mortality being 59%. Of the individuals with incident AF, only 396 were transplanted (0.5%). A Cox model was fit using year of incident AF as the covariate of interest and adjusted for years since ESRD. Nonlinear and interaction terms were explored between this covariate and incident year but they did not change the results, so a simple additive covariate was used. Table 3 shows the unadjusted and adjusted HRs for incident year. Compared with individuals whose AF was first diagnosed in 1995, those in whom it was first diagnosed in 2008 experienced a 22% (95% CI, 16 -28) lower mortality after adjustment for demographic factors (Figure 4 ).
Stroke After Newly Diagnosed Atrial Fibrillation
Of those with newly diagnosed AF, 12 346 had a stroke before their AF diagnosis date. Over 74 347 person-years of follow-up of the remaining 63 906 individuals (Figure 1 ), 7373 were hospitalized and coded for an ischemic stroke for a rate of 99 events/1000 person years. Death was a potential competing risk for stroke, as 47 506 people died before an initial stroke. Table 4 shows both the adjusted cause-specific and subdistribution HRs, all indicating substantially declining stroke rates in more recent years, albeit with wider confidence limits because of the relatively lower event rate. Compared with non-Hispanic whites, blacks, Asians, and Hispanics were all at higher risk of stroke after AF, as were men (versus women).
Discussion
Using 16 years of USRDS data, we defined the incidence of AF in older patients initiating dialysis in the United States. Newly diagnosed AF occurred at a rate of 148 events per 1000 person-years of observation and its incidence increased over time. The unadjusted 1-year probability (cumulative incidence) of newly diagnosed AF increased from 11.3% in 1995 to 14.5% in 2007. Compared with patients who initiated dialysis in 1995, the adjusted incidence of AF increased gradually until the 2003 incident ESRD cohort, who had a 16% (95% CI, 11-20) increased risk. For patients initiating dialysis in more recent years, the risk of new AF seemed to remain mostly unchanged. By contrast, the adjusted mortality after physician diagnosis of AF declined from 1995 to 2008 by 22%, but remained very high at 59% 1-year mortality in 2007. Similarly, rates of stroke after AF decreased over time, even after accounting for death as a competing risk.
Two studies reported incidence of AF in dialysis populations unrestricted by age. Abbott et al estimated a crude incidence of 12.5/1000 person years for hospitalized AF. 9 An international survey study, the Dialysis Outcomes and Practice Patterns Study (DOPPS), also studied incident AF and reported an overall incidence rate of 1 newly-diagnosed patient per 100 person-years of follow up 10 : Stratified by country, the incidence rates ranged from 0.5/100 person-years in Japan to 3/100 person years in Sweden. The US incidence was at the lower end of the range, with 0.7 new AF cases per 100 person-years. However, both studies had methodological limitations and provided no information on any putative changes of AF incidence over time.
Our findings in patients with ESRD are in contrast to similar analyses conducted in the general population of older Medicare beneficiaries. Piccini and colleagues studied the incidence of AF in Medicare fee-for-service beneficiaries over 65 years of age using a very similar outcomes definition of AF to ours. They found an incidence rate of Ϸ28/1000 person-years, which remained essentially unchanged from 1993 to 2007. 15 One-year mortality after incident AF declined slightly during that time, and was 24% in 2007. Thus, compared with the general older Medicare population, the incidence of AF in ESRD patients was 5-fold higher and the mortality after incident AF was more than double, despite an average age that was 4 years younger in the ESRD population (76 years versus 80 years). 15 There are several potential explanations for the different findings between patients on dialysis and the general older population. Given the specific circumstances of chronic dialysis treatment, it is likely that factors that are specific to the dialysis population are operational and responsible for much of this excess AF incidence compared with the general population. These factors include, but are not limited to, the following: periodic swings in fluid and electrolyte status following the current practice paradigm of providing 3 relatively short (2.5-4 hours) HD treatments per week and CI indicates confidence interval; and HR, hazard ratio. *In addition to demographic factors (age at ESRD, sex, race, Hispanic ethnicity), comorbidityadjusted model includes indicator variables for diagnosed hypertension, atherosclerotic heart disease, heart failure, cerebrovascular disease, peripheral vascular disease, diabetes mellitus, pulmonary disease, cancer, smoking, drug abuse, alcohol abuse, immobility (inability to ambulate or transfer), dialysis modality, use of an erythropoiesis-stimulating agent before initiation of dialysis, and body mass index (effect estimates for covariates not shown).
the associated neurohormonal activation and cardiac remodeling; 22 presence of a chronic state of inflammation and oxidative stress; 23, 24 and chronic disturbances of bone mineral metabolism and treatment practices that put patients at risk of chronically positive calcium balances. 25 All these factors contribute to excess (vascular and valvular) calcification and chronic fluid overload, leading to chronic stress and wear to an overfilled and increasingly stiff cardiovascular system. 26 We also found that older age was associated with increase AF incidence, whereas differences by sex were statistically significant but not clinically meaningful. By contrast, in the general older Medicare population, men experience substantially more AF, with age-standardized incidence rates of 34/1000 person-years compared with 24/1000 person-years among women. 15 Blacks (Ϫ30%), Asians (Ϫ29%), and Native Americans (Ϫ42%) were at substantially lower risk of incident AF compared with whites, the former being consistent with findings in the general population (Asians and Native Americans were not specifically studied in Piccini et al 15 ). Previous studies, including nondialysis patients, reported lower prevalence and incidence of AF in the black population despite higher burden of cardiac risk factors including hypertension, diabetes mellitus, and obesity. 8, 15, 27, 28 This observed lower AF prevalence in the black population also extends to patients with documented heart failure. 29 Marcus et al showed that European ancestry predicted risk of incident AF and suggested that genetic factors may play a role in the pathophysiology of observed AF in blacks. 30 Hispanic individuals initiating dialysis experienced a 29% lower risk of incident AF compared with otherwise similar non-Hispanics. Documenting AF trends in Hispanics is of particular interest because of their paradoxically low cardiovascular mortality despite unfavorable cardiovascular risk profiles in the dialysis population. 31 Previous studies have demonstrated that Hispanics have an increased prevalence of left ventricular hypertrophy and worse BP control, both important risk factors for AF. 32, 33 Relatively limited data are available regarding the incidence and prevalence of AF in the non-ESRD Hispanic Figure 3 . Relative annual incidences of atrial fibrillation over time. Fully-adjusted model includes indicator variables for diagnosed hypertension, atherosclerotic heart disease, heart failure, cerebrovascular disease, peripheral vascular disease, diabetes mellitus, pulmonary disease, cancer, smoking, drug abuse, alcohol abuse, immobility (inability to ambulate or transfer), dialysis modality, use of an erythropoiesis-stimulating agent before initiation of dialysis, and body mass index. 
population. A post hoc analysis of the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM) database compared baseline characteristics and outcomes of nondialysis minority populations-Hispanics were found to be younger (65.2 versus 70.3 years of age) and more frequently diagnosed with cardiomyopathy (9.1% versus 4.5%) compared with whites. 34 Thomas et al 35 recently reported a higher prevalence of cardiovascular risk factors (diabetes mellitus, hypertension) as well as nonischemic etiology of heart failure in Hispanics. Interestingly, the prevalence of AF among Hispanics was much lower (16.5 versus 35. 3) compared with non-Hispanic whites. This apparent AF paradox in Hispanics may be a reflection of less coronary artery disease or an increased prevalence of disease subtypes, such as paroxysmal AF, resulting in inadequately sensitive methods for AF diagnosis. 36, 37 Finally, differential underascertainment of AF may be the result of unequal access to care, including dialysis, leading to population bias or a selective exclusion of individuals who experience mortality related to AF. We would posit that differential ascertainment of AF in Hispanics versus non-Hispanics may not be as big of a concern in the dialysis population, because these patients receive regular treatment 3 times weekly, independent of race or ethnicity, during which they are routinely monitored for blood pressure and ECG and detection of AF is straightforward.
We found that mortality after AF decreased by 22% from 1995 to 2008, which is in contrast to a long-term study in Olmsted County (Minnesota) where mortality remained unchanged among patients who first developed AF between 1980 and 2000. 38 A more recent study of incident AF in older Medicare beneficiaries, however, also found a modest reduction in mortality after first AF between 1993 and 2007. 15 Almost one quarter (24.7%) of Medicare beneficiaries died within 1 year of first diagnosis in 2007 compared with 28.1% of those first diagnosed in 1995 (baseline year in our study), for a relative decline in mortality of 12% (age and sex standardized). 15 However, their mortality remained less than half the mortality in our cohort of dialysis patients, where mortality was 54% in 2007. Although it is nice to see a decline in mortality after AF, it is unclear what contributed to this positive trend. One may posit that increasing use of measures for secondary prevention after AF may account for some of this improvement, but a formal analysis of this hypothesis is beyond this study and what is captured in Part A and B Medicare claims.
Age was associated with increased mortality after first diagnosis of AF; however, survival of men and women was very similar. Similar to what has been shown in the general ESRD population, blacks, Asians, and Hispanics also experienced a survival advantage after incident AF compared with (non-Hispanic) whites. 31,39 -45 An important question that we tried to answer with this study is what contributed to the 3-fold increase of prevalent AF between 1996 and 2006, which we showed in another recent study. 8 It appears that 3 factors contribute to this observed increase in prevalence: we found that 38% more older individuals initiated dialysis with prediagnosed AF in more recent years, with one third of patients having been diagnosed with AF before initiation of dialysis in 2007. In addition, AF incidence after initiation of dialysis increased by Ͼ10% and mortality declined by almost one quarter among patients with diagnosed AF, meaning that more patients with new AF now alive longer, both of which increase prevalence.
We acknowledge the limitations of this study. Most importantly, we used claims to ascertain the event of interest, incident AF. Any increases in the incidence of AF, or improvements in associated risks, may reflect secular trends in the surveillance for and coding of diagnosed AF, including earlier diagnosis of this arrhythmia when patients may still be relatively healthier. We may have missed instances of silent AF, undiagnosed AF, or diagnosed but unrecorded AF. Claims data may be unable to differentiate between AF as a diagnosis requiring long-term management or AF as a sign of a transient or terminal health state. 46, 47 However, recent claims analyses have shown that even AF diagnosed at time of sepsis is strongly associated with AF-related events, such as stroke. 47 We restricted this study to patients aged Ն67 years at initiation of dialysis. These patients have been shown to be at the highest risk of AF, and any interventions reducing AF incidence would have the biggest impact in this population. Finally, although we observed a pronounced reduction over time in mortality and ischemic stroke after diagnosis of AF, data on blood pressure and antihypertensive and oral anticoagulation use were not available, and follow-up studies will be required to identify the specific causes and correlates of these improved outcomes.
In summary, AF incidence is very high, and Ϸ15% of older US dialysis patients developed AF within 1 year of dialysis initiation. Although increasing over time, especially during earlier years, its incidence has been stable over the past few years. The mortality after new diagnosis of AF has declined, but has remained excessively high at Ͼ50% in the first year after first diagnosis. Thus, identifying and testing any strategies to reduce incident AF in patients on dialysis could have a large public health impact in this vulnerable population.
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